Tracked deals
11
11 tracked deals across 2016-2026.
Biotechnology Buyers & Acquisitions in Pennsylvania
Buyer mix
Mixed buyer set
9 strategic · 8 pe
Top trend
Volume peaked in 2024
2 tracked deals announced in 2024.
Primary Insight
What Stands Out
- Kite (a Gilead Company) to acquire Interius BioTherapeutics (in vivo CAR T integration via single-infusion delivery) for $350 million.
- Cell & gene therapy manufacturing and CDMO services are a consistent focus, including SK pharmteco’s controlling interest in Center for Breakthrough Medicines (CBM) and Altaris, LLC’s purchase of advanced therapies operations (including OXGENE).
- Life-science tools and enabling tech also feature prominently: Gamma Biosciences acquiring BioMagnetic Solutions (ferrofluid immunomagnetic separation) and ARCHIMED acquiring SeqCenter (DNA/RNA sequencing).
- Strategy-and-asset platform building appears across therapeutics and enabling platforms, from oncology (DNA damage response programs) to diagnostics (food pathogen and spoilage detection).
| Theme | Examples from Pennsylvania deals |
|---|---|
| Cell & gene therapy buildout | CBM, OXGENE, ferrofluid separation via BioMagnetic Solutions |
| Enabling platforms | SeqCenter sequencing; Invisible Sentinel molecular diagnostics |
| Follow-on / investor syndicates | KKR follow-on investment in Sylvan |
| Oncology or targeted therapeutics | Interius BioTherapeutics (in vivo CAR T); Atrin Pharmaceuticals (DDR oncology) |
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| ARCHIMED | 1 | Global private equity firm focused exclusively on healthc... | PE |
| Abzena plc | 1 | Life‑sciences group / CDMO and CRO providing antibody eng... | Strategic |
| Altaris, LLC | 1 | Healthcare-focused private investment firm that acquires ... | PE |
| Altavant Sciences | 1 | Clinical-stage biopharmaceutical company focused on patie... | Strategic |
| Aprea Therapeutics, Inc. | 1 | Clinical-stage biopharmaceutical company developing and c... | Strategic |
| China Post Insurance | 1 | Insurance company and institutional investor affiliated w... | Investor |
| Gamma Biosciences | 1 | Life‑sciences tools/bioprocessing platform created by KKR... | PE |
| Gilead Sciences, Inc. | 1 | Global biopharmaceutical company with a broad oncology an... | Strategic |
| KCAS Bioanalytical and Biomarker Services | 1 | U.S.-based Contract Research Organization providing GLP-c... | Strategic (PE-backed) |
| KKR | 1 | Global alternative asset manager investing across private... | PE |
Acquisition Volume in Biotechnology in Pennsylvania by Year
Last 8 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
January 22, 2026
- Buyer
- KKR, TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee, Novo Holdings
- Target
- Sylvan
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Growth capital
KKR has completed an additional investment in Sylvan, a global mushroom spawn and fungal biotechnology company, with participation from TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee and a follow-on from Novo Holdings. The funding will support Sylvan’s expansion—increasing production capacity, strengthening R&D, developing new product categories and deeper growth across Asian markets—while KKR remains the company’s majority investor.
-
August 21, 2025
- Buyer
- Kite, Gilead Sciences, Inc.
- Target
- Interius BioTherapeutics
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
Kite, a Gilead company, entered into a definitive agreement to acquire Interius BioTherapeutics for $350 million in cash. The acquisition is intended to advance Kite’s in vivo CAR T-cell therapy platform by incorporating Interius’s integrating in vivo platform, delivered via a single intravenous infusion.
-
December 24, 2024
- Buyer
- Altaris, LLC
- Target
- Advanced Therapies (U.S. and U.K. operations of WuXi AppTec's Advanced Therapies Unit), OXGENE
- Seller
- WuXi AppTec
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Addon
Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.
-
November 8, 2024
- Buyer
- ARCHIMED
- Target
- SeqCenter
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
Global healthcare private equity firm ARCHIMED has acquired SeqCenter, a Pittsburgh, Pennsylvania-based provider of next-generation DNA and RNA sequencing, through its MED Rise fund. ARCHIMED will leverage its MedValue playbook to accelerate SeqCenter's internationalization in Europe and Asia and support further development of advanced sequencing technologies; SeqCenter's founder rolled over a significant portion of his proceeds into the business.
-
- Buyer
- SK pharmteco
- Target
- Center for Breakthrough Medicines
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
SK pharmteco is acquiring a controlling interest in cell and gene therapy CDMO Center for Breakthrough Medicines (CBM), integrating CBM with its Paris-based Yposkesi to create a global cell & gene therapy business unit. The deal expands SK pharmteco's technical capabilities, production capacity, and U.S./European footprint in advanced biologics manufacturing.
-
May 16, 2022
- Buyer
- Aprea Therapeutics, Inc.
- Target
- Atrin Pharmaceuticals Inc.
- Seller
- Atrin equity holders
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
Aprea Therapeutics, Inc. completed a stock-for-stock acquisition of privately held Atrin Pharmaceuticals, obtaining Atrin’s DNA damage response (DDR) oncology programs and proprietary discovery platform. The transaction expands Aprea’s pipeline (including ATRN-119, ATRN-354 and ATRN-W1051), adds Atrin leadership to Aprea’s management and board, and was structured to issue a mix of common stock and Series A preferred stock to former Atrin equity holders (who will own ~58.8% pro forma on an as-converted basis).
-
February 3, 2022
- Buyer
- KCAS Bioanalytical and Biomarker Services, Vitruvian Partners
- Target
- FlowMetric, LLC
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Addon
KCAS Bioanalytical and Biomarker Services, a Vitruvian Partners-backed CRO, has acquired FlowMetric, LLC, a provider of flow cytometry and cellular assay R&D services. The add-on expands KCAS's cell and gene therapy capabilities and accelerates its international footprint with FlowMetric's locations in Doylestown, Pennsylvania and Milan, Italy.
-
January 15, 2021
- Buyer
- Gamma Biosciences
- Target
- BioMagnetic Solutions
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Addon
Gamma Biosciences, the KKR-created life sciences tools platform, has agreed to acquire BioMagnetic Solutions (BMS), a State College, Pennsylvania developer of ferrofluid-based immunomagnetic cell separation systems. The acquisition brings BMS's next-generation ferrofluid affinity reagents and X-GRAFFE separation platform into Gamma's bioseparations portfolio to accelerate commercialization and scale cell- and gene-therapy manufacturing capabilities.
-
January 8, 2020
- Buyer
- Altavant Sciences, Sumitovant Biopharma Ltd.
- Target
- Onspira Therapeutics
- Seller
- Onspira Therapeutics shareholders
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
Altavant Sciences has acquired Onspira Therapeutics, adding OSP-101 — an inhaled interleukin-1 receptor antagonist with orphan drug designation for bronchiolitis obliterans syndrome (BOS) — to its rare respiratory disease pipeline. The deal closed with upfront and milestone payments to Onspira's shareholders and expands Altavant's capabilities in pulmonary transplant-related therapeutics.
-
February 7, 2019
- Buyer
- bioMérieux
- Target
- Invisible Sentinel Inc.
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
bioMérieux has acquired Invisible Sentinel Inc., a Philadelphia-based developer of Veriflow molecular diagnostic tools for food and beverage pathogen and spoilage detection, for approximately $75 million in cash. The deal strengthens bioMérieux's food pathogen testing capabilities, complements its GENE-UP molecular food testing solution and expands its reach into new customer segments such as breweries and wineries.
-
November 24, 2016
- Buyer
- Abzena plc
- Target
- The Chemistry Research Solution LLC (TCRS)
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
Abzena plc has agreed to acquire The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company based in Bristol, Pennsylvania, for $15 million plus assumed debt and share consideration. The acquisition broadens Abzena's ADC (antibody-drug conjugate) capabilities, adds US operating presence on the East Coast and creates cross-selling and GMP biomanufacturing expansion opportunities.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Frequently Asked Questions
Which biotechnology sub-sectors show up most in Pennsylvania acquisitions?
Cell & gene therapy manufacturing/CDMO services and enabling technologies (sequencing, bioseparation tools, and diagnostics) appear repeatedly, alongside selective therapeutic pipeline acquisitions.
Are there major acquisition deals involving cell and gene therapy CDMO capabilities?
Yes. SK pharmteco acquired a controlling interest in Center for Breakthrough Medicines (CBM), and Altaris, LLC acquired WuXi AppTec’s Advanced Therapies U.S. and U.K. operations (including OXGENE), with plans to combine capabilities into a larger advanced therapies platform.
Do Pennsylvania biotech deals include investors beyond U.S.-based firms?
Yes. Some transactions include global operating footprints or cross-border ambitions, and investor participation in follow-on funding includes firms such as Ping'An Capital, China Post Insurance, and Schroders Capital alongside KKR in the Sylvan investment.
What is one example of a diagnostics-focused acquisition in Pennsylvania?
bioMérieux acquired Invisible Sentinel Inc., a Philadelphia-based developer of Veriflow molecular diagnostic tools for food and beverage pathogen and spoilage detection.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2026
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2021
Acquisitions in Pennsylvania
Private Equity-Backed Acquisitions in Pennsylvania
Acquisitions in Pennsylvania in 2026